Rapid surveillance and identification of emerging SARS-CoV-2 variants using Thermo Fisher Scientific solutions
Short and longer-term impact of SARS-CoV-2 on antimicrobial stewardship
This session will focus on:
- An overview of current SARS-CoV-2 variants of concern (VOC)
- Application of the TaqMan SARS-CoV-2 Mutation Panel to quickly and easily identify VOC from positive samples
- Single-day genome sequencing of the complete SARS-CoV-2 genome for rapid detection of emerging variants
- Introduction to a case study where rapid NGS was applied to prevent the spread of the P.1 sub-lineage within Japan
Also discussed:
- Case studies on the use of antimicrobials for secondary infections to SARS-CoV-2
- Global metrics and trends associated with the use of antimicrobials with SARS-CoV-2 infections
- The importance of robust antimicrobial susceptibility testing in a clinical microbiology setting
Speakers
Jelena Feenstra, PhD
Senior Manager, Global Scientific Communications
Genetic Testing Sciences, Thermo Fisher Scientific
Jelena Feenstra, PhD is a Senior Manager, Global Scientific Communications, at Thermo Fisher Scientific. Jelena has extensive diagnostic and research experience in genetics, cytogenetics, and genomics. She has a PhD in experimental Oncology from the Medical University of Vienna and has previously worked as a Senior Scientist at the Ludwig Boltzmann Institute in Vienna. Jelena is author of over 25 publications and a recipient of several awards from professional organizations such as the American Society of Hematology as well as the UNESCO Fellowship for Women in Science.
Romney M. Humphries, PhD, D(ABMM), M(ASCP)
Professor of Pathology, Microbiology, and Immunology
Medical Director of the Microbiology Laboratory
Vanderbilt University Medical Center
Romney Humphries, PhD, D(ABMM) is a nationally recognized expert in antimicrobial susceptibility testing antimicrobial resistance (AMR). With expertise that includes improving the speed and accuracy of identifying antibiotic-resistant bacteria infecting patients to investigating novel resistance mechanisms and the evaluation of therapeutics designed to treat these critical infections, she currently serves as Medical Director of the Microbiology Laboratory at Vanderbilt University Medical Center.
Andy Felton, PhD
Vice President, Platforms, Research & Applied SBU
Clinical Sequencing Division, Thermo Fisher Scientific
Andy Felton, PhD is currently the Vice President of Product Management and Market Development for the Clinical Sequencing Division at Thermo Fisher Scientific, responsible for the development and launch of all products related to Ion Torrent next-generation sequencing systems. Andy began his career at Applied Biosystems UK Team in 1994 after completing an undergraduate degree in chemistry at Liverpool (JM) University and his PhD focused on peptide fragments of epidermal growth factor at Oxford Brooks University. In 1997 he moved to corporate headquarters in California and entered product management. During this time Andy was responsible for a number of product lines and launches, including the launch of the 7300/7500 and 7500 Fast real-time PCR systems, the 3500 and 3500 Dx genetic analyzers, eventually becoming the Director of the Capillary Electrophoresis business. Andy joined Ion Torrent in June 2010 during its start-up phase and subsequent purchase by Life Technologies.
Complete the short form below to obtain access to the ASM World Microbe Forum 2021 Industry and Science Symposia.
This product is only available to clinical laboratories conducting testing for COVID-19. Regulations prohibit us from providing this product to individual customers.